Scimed v. Cordis
This article was originally published in The Gray Sheet
Executive Summary
Oral arguments in Boston Scientific/Scimed stent patent case against Johnson & Johnson/Cordis will be heard before the D.C. federal appeals court Dec. 3. The case relates to Scimed/Medinol's NIR stent and Cordis' Express stent platforms (1"The Gray Sheet" Sept. 29, 2003, p. 3)...
You may also be interested in...
Boston Scientific Floats Taxus Base Price; J&J Counters TAXUS IV In Court
Boston Scientific is invoking clinical data from the TAXUS IV trial's diabetic patient subset to thwart Johnson & Johnson's attempt to enjoin U.S. sales of the Express2 and Taxus stents
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.